Lung Cancer Diagnostics Market Growth at 7.6% CAGR to Reach USD 22.38 Bn by 2032

Key Highlights

• The Lung Cancer Diagnostics Market was valued at USD 13.4 Bn in 2025.
• Revenue is expected to reach USD 22.38 Bn by 2032.
• The market is projected to grow at a 7.6% CAGR during 2026–2032.
• Imaging Tests are projected to grow at 8% CAGR and reach USD 2.2 Bn by the end of the analysis period.
• Hospital-associated labs held the largest end-user share in 2025.
• Non-small-cell lung cancer accounted for nearly 81% of disease occurrence.
• North America held the largest market share in 2025.
• Asia Pacific is expected to show the fastest growth rate.
• Thermo Fisher Scientific received FDA clearance for the Oncomine Dx Express Test in July 2025.

Why This Matters Now

Lung cancer diagnostics is becoming a time-to-treatment market. Hospitals, oncology networks and diagnostic companies that cannot compress imaging, biopsy and biomarker turnaround risk losing patients to faster precision-care pathways.

The market’s expansion from USD 13.4 Bn in 2025 to USD 22.38 Bn by 2032 shows that testing demand is no longer limited to disease confirmation. It is becoming the gatekeeper for therapy selection, reimbursement and clinical workflow efficiency.

Market Overview

Lung cancer begins in the lungs and most often occurs in people who smoke more. MMR lists symptoms including coughing with blood, chest pain and weight loss. These symptoms increase the need for timely detection and structured referral pathways.

Lung Cancer Diagnostics Market includes biomarker tests, imaging tests and biopsy. Biomarker tests include EGFR Mutation Test, KRAS Mutation Test, ALK Test, HER2 Test and others. Imaging includes CT scan, PET scan, chest X-ray and others, while biopsy includes needle biopsy, bronchoscopy biopsy and open biopsy.

Cost remains a barrier. The report states that many treatments are available in hospitals, but treatment cost remains too high for many people. This makes diagnostic access and government-supported hospital care important for patient pathways.

Request for sample copy of this report: https://www.maximizemarketresearch.com/request-sample/113284/

Key Trends Driving Growth

Tobacco consumption and rising cancer cases are increasing demand for diagnostics. MMR also references cervical cancer in the dynamics section, but the lung cancer diagnostics opportunity remains tied to cancer-screening awareness, imaging access and oncology infrastructure.

Awareness efforts are increasing. Governments and health organizations are spreading cancer awareness globally. That helps people who show symptoms seek diagnostic evaluation earlier.

Technology is changing workflows. The 2025 FDA clearance of Thermo Fisher Scientific’s Oncomine Dx Express Test enables rapid in-house genomic profiling with results in under 24 hours. That matters because faster mutation identification can shorten the gap between suspicion and targeted therapy selection.

AI is entering pathology. Roche received FDA Breakthrough Device Designation for an AI-powered computational pathology assay in April 2025. Imagene and Tempus also announced work on an AI-driven multi-gene panel that predicts NSCLC biomarkers directly from biopsy images.

Segment Insights

• Dominant Test Signal: Imaging Tests. Imaging Tests are described as more important for lung cancer diagnosis because they make tumor position and size easier to understand. The segment is projected to grow at 8% CAGR and reach USD 2.2 Bn by the end of the analysis period.
• Dominant End-User Segment: Hospital-Associated Labs. Hospital-associated labs held the largest share in 2025 because hospitals provide organized, documented, retrieved and logistical procedures.
• Fast-Growth End-User Signal: Hospitals. The hospital segment is expected to show fast growth due to rising private hospitals, more facilities, quick treatment and professional doctors.
• Dominant Indication Segment: Non-Small-Cell Lung Cancer. NSCLC accounted for nearly 81% of the disease, making it the largest visible indication segment.
• Other Indication Segment: Small-Cell Lung Cancer. Small-cell lung cancer is described as more aggressive than non-small-cell lung cancer, depending on gene and cell expression.
• Fastest-Growing Segment: Not disclosed. The visible MMR page does not identify a single fastest-growing test, indication or end-user segment.

Regional Growth Story

North America held the largest share of the global market in 2025. Growth is linked to increasing cancer prevalence, rising recoveries, favorable reimbursement policies and government rules in the United States and Canada.

The United States is central to the regional story. MMR cites National Cancer Institute data estimating the number of cancer cases in the United States at 1.7 million in 2025 and expected to reach 20.3 million by 2032. That scale creates demand for imaging, biomarker testing and hospital-linked oncology diagnostics.

Asia Pacific held the second-largest market share in 2025 and is expected to show the fastest growth rate. MMR links this to government policies and rising awareness among manufacturers about lung cancer diagnostics and benefits.

Europe, Middle East & Africa and South America are included in the report scope. The UK, France, Germany, China, South Korea, Japan and India are listed under regional coverage, but visible country-level revenue and reimbursement values are not disclosed.

Competitive Landscape

The market includes diagnostics companies, imaging leaders, sequencing firms, companion-diagnostic developers and oncology-focused laboratories. Key players listed by MMR include F. Hoffmann-La Roche, Thermo Fisher Scientific, Illumina, Agilent Technologies, QIAGEN, Abbott Laboratories, Bio-Rad Laboratories, NeoGenomics Laboratories, bioMérieux, Myriad Genetics, AstraZeneca, Sanofi, Johnson & Johnson, Siemens Healthineers, Danaher, Guardant Health, Veracyte, Natera, GE HealthCare, MedGenome, NanoString Technologies, Oncocyte, Boditech Med, INOVIQ and Biocartis.

Competition is shifting from single-test availability to integrated clinical decision support. Roche’s companion diagnostics, Thermo Fisher’s NGS-based test and AI-based biomarker work show a market moving toward faster molecular classification.

Rivals now need to prove diagnostic speed, biomarker breadth and compatibility with targeted therapies. Companies that connect test results to therapy selection will gain stronger oncology-network relevance.

Request for sample copy of this report: https://www.maximizemarketresearch.com/request-sample/113284/

Recent Developments

• Daiichi Sankyo and Merck received U.S. FDA Breakthrough Therapy Designation for ifinatamab deruxtecan on 18 August 2025. The move signals rising importance of diagnostic-driven therapy options for extensive-stage small-cell lung cancer.
• Thermo Fisher Scientific received FDA clearance for the Oncomine Dx Express Test on 15 July 2025. The NGS-based companion diagnostic identifies EGFR exon 20 insertion mutations and supports under-24-hour in-house genomic profiling.
• Roche Diagnostics received FDA approval for VENTANA MET (SP44) RxDx Assay on 22 May 2025. The assay identifies NSCLC patients for telisotuzumab vedotin-tllv therapy and expands actionable protein biomarker testing.
• Roche received FDA Breakthrough Device Designation for the VENTANA TROP2 RxDx Device on 14 April 2025. The AI-powered pathology assay accelerates computational biomarker evaluation.
• Imagene and Tempus announced a collaboration on 12 February 2025. Their AI-driven multi-gene panel targets NSCLC biomarker prediction directly from biopsy images.

Strategic Implications

For hospitals, diagnostics speed is now a care-quality metric. Faster imaging, biopsy and biomarker testing can reduce treatment delays.

For pharma and biotech companies, companion diagnostics are becoming market-access infrastructure. Targeted drugs need fast, validated tests to reach eligible patients.

For payers, reimbursement policy supports adoption where diagnostics improve treatment matching. Poor testing access can raise downstream cost through delayed or unsuitable treatment.

For investors, AI pathology and rapid NGS platforms are attractive because they compress oncology workflows. The best-positioned companies will link testing with therapy decisions.

Future Outlook

The Lung Cancer Diagnostics Market is positioned for expansion as cancer burden, imaging demand, biomarker testing, companion diagnostics and AI-enabled pathology increase clinical urgency. North America leads through reimbursement support and oncology infrastructure, while Asia Pacific offers the fastest growth signal through policy support and awareness.

Future leaders will shorten the path from suspicion to molecular diagnosis, while laggards will lose oncology relevance to faster, integrated diagnostic platforms.

Related Reports

Global Intragastric Balloon Market: https://www.maximizemarketresearch.com/market-report/global-intragastric-balloon-market/10873/

Collagen and Gelatin market: https://www.maximizemarketresearch.com/market-report/collagen-and-gelatin-market/162829/

Global Antibacterial Drugs Market: https://www.maximizemarketresearch.com/market-report/global-antibacterial-drugs-market/23877/

Analyst Perspective

“According to Komal Patil, Research Analyst at Maximize Market Research, ‘The Lung Cancer Diagnostics Market is projected to grow from USD 13.4 Bn in 2025 to USD 22.38 Bn by 2032 at a 7.6% CAGR, supported by cancer prevalence, imaging demand, biomarker testing, reimbursement support and companion diagnostic innovation. Hospital-associated labs lead the end-user structure, while NSCLC accounts for nearly 81% of disease occurrence. Providers that reduce diagnostic turnaround time will be better positioned.’”

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.

2nd Floor, Navale IT Park Phase 3

Pune Banglore Highway, Narhe

Pune, Maharashtra 411041, India

+91 9607365656

sales@maximizemarketresearch.com